Antibodies to the stratum corneum of rat oesophagus (antikeratin antibodies) were assayed by indirect immunofluorescence in a prospective study of patients with early rheumatoid arthritis (RA). At the beginning of the study, antikeratin antibodies of IgG class were detected in serum samples from 27/71 (38%) patients compared with 1/20 (5%) control patients with reactive arthritis, and 1/38 (3%) healthy blood donors. At the end of the two year foliow up, 27/67 (40%) patients with RA were positive for antikeratin antibodies. The patients with RA who were initially positive for antikeratin antibodies had a more active disease course than the patients negative for antikeratin antibodies as measured by clinical, laboratory, and radiological variables. The prevalence of positivity for antikeratin antibodies fluctuated during the follow up, the variation paralleling the disease activity. The occurrence of HLA-DR4 was similar in patients with RA who were positive and negative for antikeratin antibodies. Antikeratin antibodies were also found in seronegative patients with RA, confirming that antikeratin antibodies do not have rheumatoid factor activity. These results show that antikeratin antibodies are detectable at the time of the initial diagnosis of RA and that the positivity for antikeratin antibodies may have prognostic significance in early RA.
Circulating autoantibodies are found in most patients with rheumatoid arthritis (RA). Only rheumatoid factors are generally used in the diagnosis of RA, however. In the early phase of RA, rheumatoid factor is also an important prognostic marker.' 2 A number of patients with RA nevertheless remain negative for rheumatoid factor and other diagnostic and prognostic markers would be of clinical importance. During the last ten years several studies have suggested that antibodies to the stratum corneum of rat oesophagus (antikeratin antibodies) fulfil many requirements for an additional serological marker of RA.
The increased occurrence of antikeratin antibodies in patients with RA was first described by Young et al in 1979. 3 The presence of positivity for antikeratin antibodies in RA has varied in previous studies, ranging from 36 to 69%.44 Antikeratin antibodies have occasionally been found in other rheumatic diseases such as systemic lupus erythematosus,4 9 12 systemic sclerosis,8 9 12 and ankylosing spondylitiS. 812 Several workers have reported an association between disease activity assessed by various clinical and laboratory parameters and positivity for antikeratin antibodies in RA.9 10 of the incidence of antikeratin antibodies during the follow up is probably due to the variation of serum levels of antikeratin antibodies. Interestingly, this variation paralleled the disease activity; at six months follow up the occurrence of antikeratin antibodies was at its lowest and at that point the degree of clinical improvement, after treatment with disease modifying drugs, was at its highest (fig).
The diagnostic value of antikeratin antibodies has been assessed by several workers.9 13 14 IgG class antikeratin antibodies have been considered to be more specific for RA than rheumatoid factor.4 6 In our patients with early RA, the percentage ofpatients who were both rheumatoid factor negative and positive for antikeratin antibodies was low. These findings confirm, however, that antikeratin antibodies and rheumatoid factor are different antibody specificities.
In conclusion, our data suggest that in a fraction of patients with RA antikeratin antibodies are present in the early stages of disease and that in these patients antikeratin antibodies may be a marker for a more severe and active disease.
